This week's news on Quest Diagnostics, Agilent Technologies, Meridian Bioscience, Era7, DermTech, and Source Molecular.
The test is now CE marked for use in identifying patients with urothelial cancer who are most likely to benefit from Opdivo therapy.
The investment bank took note of Danaher's soft organic growth rate in the first quarter, and said it will need to build up its life science portfolio.
The companies will work together to develop a next-generation sequencing-based kit version of Agendia's molecular breast cancer diagnostics.
The firm saw 6 percent growth in its life sciences and applied markets group and 13 percent growth in its diagnostics and genomics group during the quarter.
The BRCA Mastr Plus Dx assay and Mastr Reporter software identifies mutations in the coding regions of the BRCA1 and BRCA2 genes
The test can now be used to identify patients with squamous cell carcinoma of the head and neck who are likely to benefit from Opdivo therapy.
Collaborators have created an atlas that compares available PD-L1 IHC assays and reveals areas of debate, including challenges encountered by clinicians.
At the German Society of Human Genetics annual meeting in Bochum, Berlin's Atlas Biolabs talked about its first experience with the Clarigo test.
23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.
By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.
NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.
In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.